Olon Announces the Creation of a Major Center of Research and Development in Italy, That Will Give Rise to an Innovative Global R&D Model

The Company, international API supplier, invests 10 million Euros

“The Italian R&D hub will be an international center of excellence” commented Paolo Tubertini, Olon Group CEO. “This investment is a springboard for future growth prospects guided by a clear strategic vision: innovation is our competitive edge”

MILAN, Italy – 26th of May 2022 – Olon announces the creation of an R&D hub at its center in Rodano (Milan, Italy), home to the Group’s headquarters, paving the way for further major expansion and diversification of its expertise and technologies applied to the development of APIs for the CDMO and Generics market. With a €10-million investment, the Italian Group has announced the creation of a huge area dedicated entirely to research laboratories to be used to develop API (active pharmaceutical ingredients), manufacturing processes, forming a central research hub and which, integrating with the 7 existing Olon research centers will give rise to an innovative global R&D networking model where the high-level expertise and know-how involved in specific processes, consolidated in the 11 Olon plants worldwide, will be connected, shared, and extensively applied across the Group's entire manufacturing network. The major investment involves the construction of a vast area of laboratories, some of which will focus on furthering the development of new, highly sustainable technologies, including biocatalysis and photochemistry. It will also support significant growth in the R&D team, with up to 50 new researchers hired, bringing the total number of people assigned to research activities to around 350.

Leading API supplier Olon has today announced a €10-million investment for the creation of its international research and development hub, which will cover a huge area within its site in Rodano (Milan), one of the largest in the Group's network and already highly strategic in terms of expertise in advanced manufacturing processes, high-containment technologies, and knowledge applied to process development. Construction work will get underway in May 2022 and the center will be completed, and therefore operative, in the second quarter of 2023.

The new hub represents growth in terms of people, expertise and skills, with the strategic objective of boosting internal know-how. Based on integrated data systems, this know-how will enable the company to scale up products faster and to achieve highly flexible and reliable tech transfer from one site to another. It will also facilitate the development of new molecules and innovative synthesis methods and, lastly, help the company attain more competitive process safety standards, thus increasing the safety of plants, constant product quality and ensuring business continuity.

The centre will house a number of different areas, each one dedicated to a specific field of application. The hub will include a laboratory for process safety and research into scale-up and transfer processes. It will also have an analytical R&D area, which will broaden expertise for the development of new synthesis methods and new APIs, from the early phase. Last but not least, there will be a process development laboratory with a team focusing on the development of advanced processes. All competencies will be interlinked, complementing each other, on the basis of a continuous exchange and cross fertilization model, not only within the new hub but also with the other Olon R&D centers around the world.

“Our vision is not limited to a major expansion of R&D, which is already a fundamental competitive asset for the Group today. We also aim to link the new hub up to all the other R&D centers in order to build a network of medium-sized labs that can absorb the high level of specialization and know-how of technologies specific to one site, transferring them to another. The knowledge, experience and data will be shared and exchanged, enabling application across Olon’s entire global manufacturing network,” explained Giorgio Bertolini, Senior Vice President R&D at Olon Group. “This means that each and every Olon site will benefit from the best global expertise within the Group, no matter where they are based, supporting new process development or problem-solving.”

The project involves the creation of laboratories with teams focusing on new technologies, or new technological applications, to develop innovative and highly sustainable processes for industrial production. In particular, Olon is focusing on the introduction of continuous manufacturing, biocatalysis and photochemistry. “Many of these research projects,” continued Bertolini, “will be carried out in partnership with the most prestigious Italian and foreign universities, with which we already have well-established partnerships that will be strengthened even further thanks to the new center.”

“The Italian R&D hub will be an international center of excellence in the pharmaceutical landscape,” commented Paolo Tubertini, Olon Group CEO. “This investment is a springboard for future growth prospects guided by a clear strategic vision: innovation is our competitive edge in the CDMO and Generic API market. And that is why we invest in research: we are an Italian Group, boasting the highest standards of quality, safety, and reliability in the world.”



Media Contact

Sabrina Spina

sspina@olonspa.it – mobile 338.6674289

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.


Olon Group is a global leader in the development and production of active pharmaceutical ingredients for CDMO and Generics, a reliable and preferential partner to the pharmaceutical, biotech, and specialty ingredients markets. With a 2021’s turnover of 580 Mio$, OLON supplies 300 APIs for the Generic market.

Thanks to all the 2.300 employees, and to highly qualified R&D team – more than 300 people – OLON can offer complete integrated packages and services to support the full development of APIs based on strong knowledge in both Chemical and Biological process, all of them under a full cGMP and regulatory coverage – holder of about 160 active US DMFs and 79 granted CoS.
Headquartered in Rodano (Milan, Italy), OLON has 11 manufacturing facilities - 8 located in Italy, 1 in Spain, 1 in USA and 1 in India, designed in compliance with the strictest international requirements, and 3 branch offices in Hamburg (Germany), Florham Park NJ (USA) and Shanghai (China). www.olonspa.com/